(3.236.214.19) 您好!臺灣時間:2021/05/07 13:01
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:翁茂文
研究生(外文):Mao-Wen Weng
論文名稱:肺癌患者之MDM2mRNA短小變異之研究
論文名稱(外文):Expression of MDM2 mRNA splicing variants during tumorigenesis
指導教授:柯俊良柯俊良引用關係
指導教授(外文):Jiunn-Liang Ko
學位類別:碩士
校院名稱:中山醫學院
系所名稱:毒理學研究所
學門:醫藥衛生學門
學類:其他醫藥衛生學類
論文種類:學術論文
論文出版年:2001
畢業學年度:89
語文別:中文
論文頁數:90
中文關鍵詞:抑癌基因-p53致癌基因-mdm2
外文關鍵詞:tumor suppressor gene-p53oncogene-mdm2
相關次數:
  • 被引用被引用:0
  • 點閱點閱:76
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
MDM2為人類的致癌基因,在一些腫瘤組織中經常可以發現MDM2基因的異常表現。而台灣肺癌中也發現,男性MDM2發生缺失的比例較女性高,同時在透過對肺癌組織的分析,經由篩選後選用6種不同短小缺失的MDM2,依其長度命名,分別為MDM2-1181、MDM2-1026、MDM2-1025、MDM2-891、MDM2-657、MDM2-259,並利用基因選殖的方式將上述短小缺失的MDM2與表現載體pCDNA3.0或pCDNA-HA進行接合反應,再利用DNA轉染的方式和MDM2 p53-dependent promoter一起表現於H1299/p53wt肺癌細胞株中,觀察這些短小缺失的MDM2在細胞中調控p53的情形,來分析其對於肺癌細胞可能造成的影響。結果顯示MDM2-891的luciferase表現情形與MDM2-1476相差無幾,而其它形式的MDM2則普遍低下。再進一步轉染MDM2-891、MDM2-1476及p19ARF質體DNA至H1299/p53wt肺癌細胞中並以西方轉漬法去分析p53wt表現的情形,結果顯示在單獨轉染MDM2-1476的情況下,細胞內p53蛋白明顯的減少;而在單獨轉染MDM2-891的情況下,p53的量並無明顯減少;接下來更進一步選用MDM2-657、MDM2-891與MDM2-1476質體DNA,並利用in vitro translation方式得到其所轉譯出的蛋白,其蛋白大小依序為 24.4 kDa、24 kDa與55.2 kDa,再與使用大腸桿菌所表現純化而得到的p53蛋白去進行免疫沉澱分析,發現三者對於p53蛋白均有結合反應,顯示在此兩類缺失型的胺基酸序列中尚有一未發現的部位仍具有與p53結合的能力。

The mdm2 is an oncogene that is activated by overexpression in several human tumors. In Taiwan, some distinct MDM2 mRNA transcripts including full-length RNA, splicing MDM2 forms, were detected in lung carcinomas by Nested-PCR and the ratio of MDM2 deletion mutants in male were higher than in female. To understand the biological function of the splicing MDM2 forms that may play the role in tumorigenesis, We had also cloned several splicing MDM2 protein translations(MDM2-1181,MDM2-1026,MDM2-1025,MDM2-891,MDM2-657,MDM2-259), and H1299/p53wt cell were transfected with these splicing MDM2 plasmids and MDM2 p53-dependent promoter. We analyzed the characterization with its ability to regulate p53 via luciferase activity assay. The result show, MDM2-891 exhibited the luciferase activity similar with MDM2-1476, but others was not. We present evidence to show if the MDM2-1476 and MDM2-891 expressed from their respective cDNA could degrade the wt p53 . H1299/p53wt cells were transfected with MDM2-1476, MDM2-891 and p19ARF plasmids and analyzed the expression of p53 protein by Western Blotting. These result show, p53 protein was degraded by MDM2-1476, but not degraded by MDM2-891. We analyzed the molecular weight of MDM2 trunscated forms by in vitro translation and use the products to immunoprecipitate with p53 protein which is amplified from E.coli expression system and purified from Glutathione-Sepharose 4B affinity column. Our findings indicated the presence of the splicing MDM2 forms which could bind to p53 protein. It showed that MDM2-891 and MDM2-657 might keep a serious of unknow sequences which could bind to p53 protein. These observations suggest that MDM2 expression is altered in lung carcinomas and the cellular roles of these trunscated MDM2 isoforms remains not to be clarified.

一、縮寫表-------------------------------------------------------------------4
二、中文摘要--------------------------------------------------------------- 5
三、英文摘要--------------------------------------------------------------- 7
四、緒言--------------------------------------------------------------------- 9
五、研究動機--------------------------------------------------------------- 22
六、實驗材料與儀器------------------------------------------------------ 25
七、實驗方法--------------------------------------------------------------- 28
八、實驗結果--------------------------------------------------------------- 51
九、討論--------------------------------------------------------------------- 58
十、圖表及圖表說明------------------------------------------------------ 67
十一、參考文獻--------------------------------------------------------------- 82

1. Agarwal, M. L., Agarwal, A., Taylor, W. R., and Stark, G. R.(1995) p53 controls both the G2/M and G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci., USA 92:8493-8497.
2. Barak Y. Juven T. Haffner R. Oren M.(1993) MDM2 expression is induced by wild type p53 activity. EMBO. J., 12(2):461-468.
3. Bishop, M.(1991)Molecular themes in oncogenesis. Cell, 64, 235-248.
4. Bueso-Ramos, C., Manshouri, T., Haidar, M., Yung, Y., McCOWN, P., Ordonez, N., Glassman, A., Sneige, J., and Albitar, M.(1996) Abnormal expression of mdm2 in breast carcinomas. Breast Cancer Res. Treat., 37: 179-188.
5. Bueso-Ramos,C. E., Y. Yang, E. deleon, P. McCown, S. A. Stass, and M. Albitar.(1993) The human MDM-2 oncogene is overexpressed on leukemias. Blood 82: 2617-2623.
6. Bueso-Ramos, C., Manshouri, T., Haidar, MA. Huh YO. Keating MJ. Albitar M.(1995) Multiple patterns of MDM-2 deregulation in human leukemias:implications in leukemogenesis and prognosis. Leukemia Lymphoma. 17(1-2):13-18.
7. Buurch, L., Midgley, C., Currie, R., Lane, D., and Hupp, T. mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett., 472: 93-98.
8. Carol Prives.(1998) Signaling to p53: Breaking the MDM2-p53 Circuit. Cell, 95:5-8.
9. Cahlly-Snyder, L., Yang-Feng, T., Francke, U. & George, D. L.(1987). Som. Cell Mol. Gen., 13, 235-244.
10. Cordon-Cardo, C. et al.,(1994) Molecular abnormalities of mdm2 and p53 gene in adult soft tissue sarcomas. Cancer Research. 54: 794-799.
11. Chen J, Marechal V and Levine AJ.(1993). Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol., 13:4107-4114.
12. Chen, P. L., Chen, Y. M., Bookstein, R., and Lee, W. H.,(1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250:1576-1580.
13. Diller, L., Kassel, J., and Nelson, C. E.(1990) p53 function as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10:5772-5781.
14. David C. Olson, Vincent Marechal, Jamil Momand, Jiandong Chen, Cathleen Romocki & Arnold J. Levine.(1993) Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene. (8): 2353-2360.
15. Doris R. Brown, Charles A. Thomas and Swati Palit Deb.(1998) The human oncoprotein MDM2 arrests the cell cycle:elimination of its cell-cycle-inhibitory function induces tumorigenesis. The EMBO J., 17:2513-2525.
16. Dubbelstein, M., Roth, J., Kimberly, W. T., Levine, A. J. and Shenk, T.(1997) Nuclear export of the E1B 55-kDa and E4 34-kDa adevoviral oncoproteins mediated by a rev-like signal sequence. The EMBO J., 16:4276-4284.
17. Deleo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J.(1979) Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci., USA 76:2420-2424.
18. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B.(1992) Definition of a consensus binding site for p53. Nature, Gene., 1:45-49.
19. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B.(1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75:817-825.
20. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T., and Levine, A. The mdm2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med., 2:439-451.
21. Finlay, C. A., Hinds, P. W., and Lecine, A. J.(1989) The proto-oncogene can act as a suppressor of tansformation. Cell,57:1083-1093.
22. Fakharzadeh SS. Trusko SP. George DL.(1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10(6):1565-1569.
23. Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj.(1997) CRM1 is an export receptor for leucine-rich nuclear export signals. Cell (90):1051-1060.
24. Fukuda, M., S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and E. Nishida.(1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308-311.
25. Foulkes WD. Stamp GW. Afzal S. Lalani N. Mcfarlane CP. Trowsdale J. Caampbell IG.(1995) MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Brit. J. Cancer. 72(4):883-888.
26. Gudas, J., Nguyen, H., Klein, R., Katayose, D., Seth, P., and Cowan, K. (1995) Differential expression of multiple mdm2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin.Cancer Research. 1:71-80.
27. Gorgoulis VG. Zoumpourlis V. Rassidakis GZ. Karameris A. Rassidakis AN. Spandidos DA. Kittas C.(1996) A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in brinchogenic carcinoma. J. Pathol. 180(2):129-137.
28. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., and Sorlie, T.(1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic, Acids, Res., 22:3551-3555.
29. Honda R and Yasuda H.(1999)Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J., 18:22-27.
30. Honda R, Tanaka H and Yasuda H.(1997)Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420:25-27.
31. Haupt Y, Barak Y and Oren M.(1996)Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J., 15:1596-1606.
32. Harris CC.(1996) Structure and function of the p53 tumor suppressor gene: clus for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88(20):1442-1455.
33. Hunter, T.(1991) Cooperation between oncogenes. Cell, 64,249-270.
34. Judith Roth. Mattias Dobbelstein. Deborah A. Freedman. Thomas Shenk and Arnold J. Leevine.(1998) Nucleo-cytoplasmic shuttling of the mdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17:554-564.
35. Kastan MB. Onyekwere O. Sidransky D. Voogelstein B. Craig RW.(1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Research. 51(23):6304-6311.
36. Kastan, M. B., Zhan, Q., and El-Deiry, W. S.(1992) A mammalian cell cycle checkpoint pathway itilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71:587-597.
37. Lambert, S., Saintigny, Y., Delacote, F., Amiot, F., Lecomte, M., Huck, S., Bertrand, P., and Lopez, B.(1999) Analysis of intrachromosomal homologous recombination in mammalian cell,using tandem repeat sequences. Mutat. Res., 433:159-168.
38. Landers JE. Cassel SL. George DL. (1997)Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Research. 57(16):3562-3568.
39. Lundgren, K., Montes de Oca Luna, R., NcNeill, Y., Emerick, E., Spencer, B., Barfield, C., Lozano, G., Rosenburg, M.,and Funlay, C.(1997) Targeted expression of mdm2 uncouples S phase from mitosis and inhibits mammary gland development indendent of p53. Genes, & Dev., 11:714-725.
40. Lane, D. P.(1992) p53, guardian of the genome. Nature, 358:15-16.
41. Levine, A. J.(1997) p53,the cellular gatekeeper for growth and division. Cell, 88:323-331.
42. Lu X. Lane DP.(1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation:defects in chromosome instability syndromes. Cell. 75(4):765-768.
43. Linardopoulos, S., Street, A., Quelle, D. E., Parry, D., Peters, G., Sherr, C. J. and Balmain, A.(1995)Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Research. 55,5168-5172.
44. Midgley, C. A., and Lane, D. P.(1997) p53 protein stability in tumor cells is not determined by mutation but is dependent on MDM2 binding. Oncogene, 15:1179-1189.
45. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., and Ullrich, S. J.(1990) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl Acad. Sci. USA 87: 6166-6170.
46. Maki CG. Huibregtse JM. Howley PM.(1996)In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Research.56(11):2649-2654.
47. Maltzman W. Czyzyk L.(1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4(9): 1689-1694.
48. Miyashita T. Reed JC.(1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80(2):293-299.
49. Matsumoto R. Tada M. Nozaki M. Zhang CL. Sawamura Y. Abe H.(1998) Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Research. 58(4):609-613.
50. Manuela Argentini, Nadia Barboule and Bohdan Wasylyk. (2000)The contribution of the RING finger domain of MDM2 to cell cycle progression. Oncogene 19:3849-3857.
51. Mary Ellen Perry, Susan M. Mendrysa, Leslie J. Saucedo, Paul Tannous, and Marisa Holubar.(2000) p76MDM2 inhibits the ability of p90MDM2 to destabilize p53. The J. B. C. Vol 275,(8):5733-5738.
52. Martin K. Trouche D. Hagemeier C. Kouzarides T.(1995) Reegulation of transcription by E2F/DP1. J. Cell Sci. 19:91-94.
53. Marechal V. Elenbaas B. Piette J. Nicolas JC. Levine AJ.(1995) The ribosomal L5 protein is associated with mdm2 and mdm2-p53 complex. Mol. Cell. Biol. 14(11):7414-7420.
54. Momand J. Zambetti GP. Olson DC. George D. Levine AJ.(1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69(7):1237-1245.
55. Martinez, J., Georgoff, I., Martinez, J. & Levine, A. J. (1991) Genes, & Dev., 5, 151~159.
56. Oliner JD. Kinzler KW. Meltzer PS. George DL. Vogelstein B.(1992) Amplification of a gene encoding a p53-associated protein in human sarcomas . Nature. 358(6381):80-83.
57. Olson, D. C., Marechal, V., Momamd, J., Chen, J., Romocki, C. and Levine, A. J.(1993)Identification and characterization of miltiple MDM2 proteins and MDM2-p53 protein complexes. Oncogene, 8, 2353-2360.
58. Okamoto, K., and Beach, D.(1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO. J., 13:4816-4822.
59. Oren, M., Reich, N. C., and Levine, A. J.(1982) Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progency. Mol. Cell. Biol., 2:443-449.
60. Prives, C., and Manfredi, J. J. (1993)The p53 tumor suppressor protein: meeting review. Genes, & Dev., 7:529-534.
61. Pinkas, J., Naber, S., Butel, J., Medina, D., and Jerry, D.(1999)Expression of mdm2 during mammary tumorigenesis. Int. J. Cancer, 81:292-298.
62. Quelle, D. E. et al.,(1995)Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene, 11,635-645.
63. Reznikov, M. V., Fidler, R., Rubtsov, P. M., Skriabin, K. G., Chumakov, P. M., Prasolov, V S., and Baev, A. A.(1989) Expression of human growth hormone in cultured mouse fibroblasts. Molekuliarnaia Biol.,(Mosk), 23:1692-1699.
64. Scheffer, M., Nuber, U., and Huibregtse, J. M.(1995) Protein ubiquitination involving an E1-E2-E3 ubiquitin thioester cascade. Nature(Lond.),(373):81-83.
65. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. and Lowe, S. W.(1997)Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88, 593-602.
66. Sigalas, I., Calvert, A., Anderson, J., Neal, D., and Lunec, J.(1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Net. Med., 2: 912-917.
67. Sigalas,I. and Lunec,J.(1995)Multiple alternate spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. JOURNAL Unpublished.
68. Soussi, T., Caron, de, Fromentel, C., and May, P.(1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5:945-952.
69. Soussi, T., and May, P.(1996) Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol., 260:623-637.
70. Selivanova ,G., Iotsova, V., Okan, I., Fritsche, M., Strom, M., Groner, B., Grafstrom, R. C., and Wiman, K. G.(1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature, Med., 3:632-638.
71. Selvakumaran M. Lin HK. Miyashita T. Wang HG. Krajewski S. Reed JC. Hoffman B. Liiebermann D.(1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptoctic pathway. Oncogene. 9(6):1791-1798.
72. Tran, H., Gordenin, D., and Resnick, M. The prevention of repeat-associated deletions in Saccharomyces cerevisiae by mismatch repair depend on size and origin of deletions. Geenetics,143:2579-1587.
73. Vogelstein, B., and Kinzler, K. W.(1992) Carcinogens leave fingerprints. Nature 355:209-210.
74. Vogelstein, B., and Kinzler, K. W.(1992) p53 function and dysfunction. Cell,70:523-526.
75. Wang XW. Vermeulen W. Coursen JD. Gibsion M. Lupold SE. Forrester K. Xu G. Elmore L. Yeh H. Hoeijmakers JH. Harris CC.(1996) The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes, & Dev., 10:1219-1232.
76. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J.(1993) The p53-mdm2 autoregulatory feedback loop. Genes, & Dev., 7:1126-1132.
77. Xiao, Z., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M.(1995)Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375, 694-698.
78. Zhang, Y., Xiong, Y., and Yarbrough, W. G.(1998)ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways. Cell 92,725-734.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
系統版面圖檔 系統版面圖檔